116
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Advances and Challenges of Liposome Assisted Drug Delivery

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The application of liposomes to assist drug delivery has already had a major impact on many biomedical areas. They have been shown to be beneficial for stabilizing therapeutic compounds, overcoming obstacles to cellular and tissue uptake, and improving biodistribution of compounds to target sites in vivo. This enables effective delivery of encapsulated compounds to target sites while minimizing systemic toxicity. Liposomes present as an attractive delivery system due to their flexible physicochemical and biophysical properties, which allow easy manipulation to address different delivery considerations. Despite considerable research in the last 50 years and the plethora of positive results in preclinical studies, the clinical translation of liposome assisted drug delivery platforms has progressed incrementally. In this review, we will discuss the advances in liposome assisted drug delivery, biological challenges that still remain, and current clinical and experimental use of liposomes for biomedical applications. The translational obstacles of liposomal technology will also be presented.

          Related collections

          Most cited references146

          • Record: found
          • Abstract: found
          • Article: not found

          Liposomal drug delivery systems: from concept to clinical applications.

          The first closed bilayer phospholipid systems, called liposomes, were described in 1965 and soon were proposed as drug delivery systems. The pioneering work of countless liposome researchers over almost 5 decades led to the development of important technical advances such as remote drug loading, extrusion for homogeneous size, long-circulating (PEGylated) liposomes, triggered release liposomes, liposomes containing nucleic acid polymers, ligand-targeted liposomes and liposomes containing combinations of drugs. These advances have led to numerous clinical trials in such diverse areas as the delivery of anti-cancer, anti-fungal and antibiotic drugs, the delivery of gene medicines, and the delivery of anesthetics and anti-inflammatory drugs. A number of liposomes (lipidic nanoparticles) are on the market, and many more are in the pipeline. Lipidic nanoparticles are the first nanomedicine delivery system to make the transition from concept to clinical application, and they are now an established technology platform with considerable clinical acceptance. We can look forward to many more clinical products in the future. Copyright © 2012 Elsevier B.V. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Liposomes as nanomedical devices

            Since their discovery in the 1960s, liposomes have been studied in depth, and they continue to constitute a field of intense research. Liposomes are valued for their biological and technological advantages, and are considered to be the most successful drug-carrier system known to date. Notable progress has been made, and several biomedical applications of liposomes are either in clinical trials, are about to be put on the market, or have already been approved for public use. In this review, we briefly analyze how the efficacy of liposomes depends on the nature of their components and their size, surface charge, and lipidic organization. Moreover, we discuss the influence of the physicochemical properties of liposomes on their interaction with cells, half-life, ability to enter tissues, and final fate in vivo. Finally, we describe some strategies developed to overcome limitations of the “first-generation” liposomes, and liposome-based drugs on the market and in clinical trials.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Nanoparticles in medicine: therapeutic applications and developments.

              Nanotechnology is the understanding and control of matter generally in the 1-100 nm dimension range. The application of nanotechnology to medicine, known as nanomedicine, concerns the use of precisely engineered materials at this length scale to develop novel therapeutic and diagnostic modalities. Nanomaterials have unique physicochemical properties, such as ultra small size, large surface area to mass ratio, and high reactivity, which are different from bulk materials of the same composition. These properties can be used to overcome some of the limitations found in traditional therapeutic and diagnostic agents.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Pharmacol
                Front Pharmacol
                Front. Pharmacol.
                Frontiers in Pharmacology
                Frontiers Media S.A.
                1663-9812
                01 December 2015
                2015
                : 6
                : 286
                Affiliations
                [1] 1The School of Biomedical Sciences and Pharmacy, The University of Newcastle Callaghan, NSW, Australia
                [2] 2Hunter Medical Research Institute, New Lambton Heights NSW, Australia
                [3] 3Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA
                [4] 4Department of Biochemistry and Cell Biology, Rice University Houston, TX, USA
                [5] 5Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center Houston, TX, USA
                [6] 6Department of Cancer Biology, The University of Texas MD Anderson Cancer Center Houston, TX, USA
                Author notes

                Edited by: Aaron Tan, University College London, UK

                Reviewed by: Zejing Wang, Fred Hutchinson Cancer Research Center, USA; Robert Lust, East Carolina University, USA

                *Correspondence: Susan Hua susan.hua@ 123456newcastle.edu.au

                This article was submitted to Integrative and Regenerative Pharmacology, a section of the journal Frontiers in Pharmacology

                Article
                10.3389/fphar.2015.00286
                4664963
                26648870
                853312ad-e4a0-43dd-92d4-e34a2c4513a3
                Copyright © 2015 Sercombe, Veerati, Moheimani, Wu, Sood and Hua.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 31 July 2015
                : 16 November 2015
                Page count
                Figures: 1, Tables: 1, Equations: 0, References: 129, Pages: 13, Words: 11435
                Categories
                Pharmacology
                Review

                Pharmacology & Pharmaceutical medicine
                liposomes,drug delivery,lipid-based drug delivery system,nanotechnology,biological challenges,translation,accelerated blood clearance,complement activation–related pseudoallergy

                Comments

                Comment on this article